Dec. 9 at 7:01 PM
Just read this on
$SRTS
Investors cheering “CMS raise” on SRTS may have missed the fine print: when you add back the deleted CPT ancillaries, the real reimbursement per treatment drops by roughly 66%.
SRTS: CMS boosted the
$40-50 77401 code, but wiped out ~
$600 in add-on fees per fraction (77280, G6001 and friends) - that is not a bullish math problem for new machine demand.
If your SRTS thesis is “reimbursement went up,” you need to see the CPT stack that just got nuked and why only the very highest volume SRT centers can survive under the new rule.
SRTS stock has been sliding while quarterly earnings trend down 2 quarters in a row and the new CMS rule guts economics for SRT/IG-SRT delivery - are you sure you know what you own?
“Revenue headwind” is an understatement: for SRTS customers, the same skin cancer treatment now pays about one third of what it did before, making fresh capex on new SRT boxes a very hard sell.
